Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 3Genitourinary 1Gastrointestinal 1

Conditions

Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Cervical Neoplasms 1Recurrence 1Penile Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 35Nivolumab 13Cyclophosphamide 11fludarabine 9aldesleukin 9atezolizumab 7Magnetic Resonance Spectroscopy 7Carboplatin 7Specimen Handling 6Ipilimumab 6Early Intervention, Educational 6Cisplatin 6Trastuzumab 5Paclitaxel 5Methods 5Biopsy 5Bevacizumab 5durvalumab 4Vaccines 4Surveys and Questionnaires 4Radiotherapy 4Papillomavirus Vaccines 4Interleukin-2 4Docetaxel 4tisotumab vedotin 3spartalizumab 3fludarabine phosphate 3cemiplimab 3aflibercept 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × MEDI0457 × Gastrointestinal × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡